Psychiatry Editorial
  • Home
  • News
  • About
  • Contact

Komodo Health Appoints Richard Kho as Chief Revenue Officer and Saiba Sabherwal as Chief Financial Officer

Press Releases Komodo, Telemedicine

Company Also Adds Julie Rogers as Vice President of People & Experience

San Francisco, Calif., October 18, 2018 – Komodo Health™, the leading healthcare AI company, announced today the promotions of Richard Kho, Ph.D., as chief revenue officer and Saiba Sabherwal, M.B.A., as chief financial officer. In addition, the company announced the strategic hire of Julie Rogers as vice president of people & experience. Since its founding in 2014, Komodo Health has grown to more than 90 employees with offices in San Francisco and New York.

Dr. Richard Kho steps into the chief revenue officer position from his most recent post as head of life sciences. In his new role, Dr. Kho will lead the customer team and oversee the sales, account management, and customer success functions. He brings more than 18 years of in-depth experience in life sciences, including roles at Genentech and Onyx Pharmaceuticals.

Promoted to chief financial officer from her previous role as head of operations, Saiba Sabherwal will lead all finance functions. Ms. Sabherwal brings more than 15 years of experience between the financial services and tech industries, including senior roles at Google, Spotify, and Pandora – where she helped scale the company for its initial public offering.

“Richard and Saiba have been integral in the growth of Komodo Health over the last several years,” said Arif Nathoo, M.D., CEO and co-founder of Komodo Health. “Richard has a keen understanding of the life sciences space and is a trusted partner to our clients. Saiba is an expert financial advisor who has helped manage our growth plan and brings tremendous SaaS-related expertise. We are thrilled to have them in their new executive roles.”

Komodo Health also welcomed Vice President of People & Experience Julie Rogers, who will oversee all human resources functions and is tasked with innovating culture initiatives and motivating team members to find success within the organization. She brings more than 20 years of human resources knowledge and leadership from positions at Culture Amp, Atlassian, and AdRoll.

“Culture at Komodo Health is at its core about believing that our people are instrumental to our business success,” said Nathoo. “We believe strongly that talented people only thrive in a healthy and challenging environment, and Julie comes to us with a great reputation for fostering and guiding motivated, high-performance teams.”

About Komodo Health
Komodo Health is a leading healthcare AI company focused on improving patient outcomes and reducing global burden of disease through the largest, most representative, and timeliest healthcare map. Komodo Health was founded in San Francisco in 2014 and is backed by IA Ventures, Felicis Ventures, and McKesson Ventures. To learn more, visit komodohealth.com.

SOURCE: Komodo Health

Related Posts

Press Releases

Teladoc Health to Acquire InTouch Health

Press Releases

Vivante Health Snags DebraAnn Braun as Chief Technology Officer

Press Releases

Dr. Jason Hallock Joins SOC Telemed as Chief Medical Officer

Featured News

  • Teladoc Health to Acquire InTouch Health
  • Vivante Health Snags DebraAnn Braun as Chief Technology Officer
  • Dr. Jason Hallock Joins SOC Telemed as Chief Medical Officer
  • Change Healthcare Unveils API & Services Connection, a Marketplace to Accelerate Innovation in Healthcare
  • Gemelli Hospital on Track to Become More Digitized for Better Patient Management

Elevator Talks: New Drugs

  • Alkermes Initiates Rolling Submission of ALKS 5461 New Drug Application for Major Depressive Disorder
  • Alkermes Announces Positive Preliminary Topline Results From Phase 3 Antipsychotic Efficacy Study of ALKS 3831 for Treatment of Schizophrenia
  • Alkermes Announces Initiation of Study 217 for ALKS 5461 for Treatment of Major Depressive Disorder
  • Alkermes Announces Initiation of Phase 3 Study of ALKS 3831 in Young Adult Patients
  • FDA Approves Two-Month ARISTADA® for Treatment of Schizophrenia
Psychiatry Editorial
Copyright © PhysicianEditorial.com
All Rights Reserved!